KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $51.0 million.

  • Jazz Pharmaceuticals' Change in Receivables rose 12913.37% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.6 million, marking a year-over-year decrease of 5935.88%. This contributed to the annual value of $21.1 million for FY2024, which is 5930.27% down from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Change in Receivables stood at $51.0 million for Q3 2025, which was up 12913.37% from $55.5 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Change in Receivables' 5-year high stood at $75.5 million during Q4 2023, with a 5-year trough of -$66.0 million in Q1 2025.
  • For the 5-year period, Jazz Pharmaceuticals' Change in Receivables averaged around $15.6 million, with its median value being $16.6 million (2021).
  • The largest annual percentage gain for Jazz Pharmaceuticals' Change in Receivables in the last 5 years was 73668.58% (2025), contrasted with its biggest fall of 88229.3% (2025).
  • Jazz Pharmaceuticals' Change in Receivables (Quarter) stood at $64.8 million in 2021, then fell by 28.58% to $46.3 million in 2022, then soared by 63.11% to $75.5 million in 2023, then tumbled by 101.14% to -$864000.0 in 2024, then soared by 6002.31% to $51.0 million in 2025.
  • Its Change in Receivables stands at $51.0 million for Q3 2025, versus $55.5 million for Q2 2025 and -$66.0 million for Q1 2025.